Clinical trials: Bulbar Disease
Amyotrophic Lateral Sclerosis (ALS)
Clinical Trial Nuedexta in Subjects With ALS
The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01806857
- Testing
- Nuedexta
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Center for Neurologic Study, La Jolla, California,
Bronchiolitis, Respiratory Disease
Nasal Suction in Infants With Bronchiolitis Using a NoseFrida vs. Bulb Syringe
This research study will evaluate the difference in effectiveness of nasal suction between two different suction devices (NoseFrida and bulb syringe) in infants that have bronchiolitis.
- Trial name
- NCT04599101
- Testing
- Nose Frida nasal suction device, Bulb syringe nasal suction device
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Corewell Health East
Muscular Atrophy, Spinal
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
This was a phase IV Open-label, single-arm, single-dose, multicenter study, to evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with SMA with bi-allelic mutations in…
- Trial name
- OFELIA (NCT05073133)
- Testing
- OAV101
- Where
- 5 sites in Argentina, Brazil
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Premature Rupture of Membranes
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Multicenter randomized clinical trial comparing oxytocin versus oxytocin and foley catheter for induction in women who present with premature rupture of membranes who are not in labor.
- Trial name
- FOLCROM (NCT01973036)
- Testing
- Foley Catheter, Oxytocin
- Where
- 5 sites in United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
A Study of NIDO-361 in Patients With SBMA
The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).
- Trial name
- PIONEER KD (NCT06411912)
- Testing
- NIDO-361
- Where
- 5 sites in Denmark, Italy and 2 more
- Volunteers
- 54 people
- Sponsor
- Nido Biosciences, Inc.
Amyotrophic Lateral Sclerosis
Impact of Nuedexta on Bulbar Physiology and Function in ALS
Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported.
- Trial name
- NCT03883581
- Testing
- dextromethorphan HBr and quinidine sulfate
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida
Cutaneous T-Cell Lymphoma
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
- Trial name
- NCT02448381
- Testing
- SGX301 (synthetic hypericin)
- Where
- 33 sites in United States
- Volunteers
- 169 people
- Sponsor
- Soligenix
Spinal and Bulbar Muscular Atrophy
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
- Trial name
- NCT02024932
- Testing
- BVS857
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Kennedy's Disease, Spinal and Bulbar Muscular Atrophy
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
This study will determine if the drug dutasteride can improve weakness, mobility, functioning, nerve function, and quality of life in patients with spinal and bulbar muscular atrophy (SBMA).
- Trial name
- NCT00303446
- Testing
- Dutasteride
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Cerebral Hypoxia, Postoperative Cognitive Dysfunction
The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane
the purpose of this study is to investigate whether propofol and sevoflurane have difference effect on cerebral oxygenation .
- Trial name
- NCT01757561
- Testing
- propofol, sevoflurane
- Where
- China
- Volunteers
- 144 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Spinal Muscular Atrophy
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
To evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene weighing ≥…
- Trial name
- SMART (NCT04851873)
- Testing
- OAV101
- Where
- 13 sites in United States, Australia and 7 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, ALS
Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)
Prospective, international, randomised, double-blind, placebo controlled, multicentre, parallel group study. Patients will be randomised in a 2:1 allocation ratio to receive either IFB-088 + riluzole 100 mg or placebo + riluzole…
- Trial name
- NCT05508074
- Testing
- IFB-088 50mg/day, Riluzole 100mg/day
- Where
- 9 sites in France, Italy
- Volunteers
- 51 people
- Sponsor
- InFlectis BioScience
Spinal Muscular Atrophy
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam
This was a Phase IIIb open-label, single arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101B in participants with SMA aged 2 to <18 years after the discontinuation of treatment with nusinersen or…
- Trial name
- STRENGTH (NCT05386680)
- Testing
- OAV101
- Where
- 13 sites in United States, Australia and 7 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals